Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Onward with OINV candidate
10-11-2017
SHARING OPTIONS:

JUPITER, Fla.—Charleston Laboratories Inc. has reacquired all U.S. development and commercialization rights to its hydrocodone pipeline products from Daiichi Sankyo Co. Ltd. and Daiichi Sankyo Inc., its U.S. subsidiary. This transaction concludes the companies’ three-year collaboration. Charleston Laboratories is moving to bring CL-108, its lead candidate, to market, with plans to submit a New Drug Application soon. The compound is being developed to treat pain that requires an opioid analgesic while preventing or reducing opioid-induced nausea and vomiting (OINV).
 
“By addressing OINV, we believe that patients will achieve proper pain relief, shortened recovery time and fewer days on opioid medication. Through decreasing a patient’s use of opioids, we aim to reduce the risk of misuse and abuse. Charleston Laboratories is dedicated to ensuring safe and responsible prescribing and use of our opioid analgesic portfolio,” said Paul Bosse, company president and CEO.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.